Pershing Square Portfolio (multi-position annual update)

Slide locked Sign in to view

Slide schematic 5/6

callout 2/3 list 2/2 title 1/1

1 without position callout 1

callout

Components 6

primary primary callout bullet bullet headline

Tools 1

Thesis archetype slide · 70%

callout/primary: Strategic rationale of a Valeant/Allergan merger

Metrics 0

∅

No metrics

No metric insight is anchored to this slide.

Frameworks 1

Mentions capital allocation strategy and cost management as key drivers for merger value.

Find anything